Keywords: Immune-mediated adverse events; Agranulocytosis; Neutropenia; Immune checkpoint inhibitors; Nivolumab;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Microsatellite instability; Nivolumab; PD-L1; Pembrolizumab; TILs;
Keywords: Immune checkpoint inhibitors; Nivolumab; Atezolizumab; Pembrolizumab; Renal cell carcinoma; Urothelial carcinoma;
Keywords: Immuno-oncology; T-cell receptors; Novel evaluation criteria; Ipilimumab; Nivolumab; Combinations; AE; Adverse events; APC; Antigen-presenting cell; BMS; Bristol-Myers Squibb; CR; Complete response; CTLA-4; Cytotoxic T-lymphocyte antigen 4; DTIC; Dacarbaz
Keywords: Ipilimumab; Tremelimumab; Nivolumab; Immunotherapy; Checkpoint inhibitor; Anti-PD-1; Anti-PD-L1; Anti-CTLA4;
Keywords: Immunotherapy; Non-small cell lung cancer; PD-L1; CTLA-4; Ipilimumab; Nivolumab;
Keywords: Brentuximab vedotin Pembrolizumab; Nivolumab; Everolimus; Hodgkin lymphoma
Keywords: granulomatosis; melanoma; nivolumab; PD-1CTLA, cytotoxic T-lymphocyte-associated protein; PD-1, anti-programmed death 1; Th1, T helper 1
Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series
Keywords: Ovarian cancer; Recurrence; BRCA mutation carrier; Salvage therapy; Nivolumab;
Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy
Keywords: anti-PD-1 antibody; granulomatous; immune-related; melanoma; nivolumab; panniculitis; PET/CT; positron emission tomography/computed tomography;
Severe interstitial pneumonia associated with anti-PD-1 immune checkpoint antibody after talc slurry pleurodesis
Keywords: SqCC; squamous cell carcinoma; anti-PD-1; anti-programmed death-1; irAE; immune-related adverse event; PS; Eastern Cooperative Oncology Group performance status; CRP; C-reactive protein; LDH; lactate dehydrogenase; CT; computed tomography; VC; vital capac
Uvéite bilatérale associée à un traitement par nivolumab
Keywords: Dysfonctionnement meibomien; Chirurgie de la cataracte; Sécheresse oculaire; Meibographie; Expressibilité meibomienne; Uveitis; Drug induced uveitis; Posterior uveitis; Nivolumab; Anti-PD1; Chemotherapy; Check point inhibitors;
Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy
Keywords: Anal cancer; Immunotherapy; Nivolumab; Anti-EGFR; Cetuximab; Pembrolizumab; Panitumumab;
Nivolumab-induced alopecia areata: A reversible factor of good prognosis?
Keywords: alopecia areata; anti-programmed cell death protein-1; drug adverse event; immune related; lung cancer; melanoma; nivolumab; AA; alopecia areata; CTLA-4; cytotoxic T-lymphocyte-associated antigen-4; ICI; immune checkpoint inhibitors; PD-1; programmed
Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer
Keywords: NSCLC; non-small cell lung cancer; IrAE; immune-related adverse event; PFS; progression-free survival; OS; overall survival; CMI; Charlson's comorbidity index; ECOG; Eastern Cooperative Oncology Group; ADR; adverse drug reaction; SAE; serious adverse even
Nivolumab-induced acute demyelinating polyradiculoneuropathy mimicking Guillain-Barré syndrome
Keywords: Nivolumab; Immune checkpoint inhibitor; Guillain-Barré syndrome; Polyneuropathy;
Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients
Keywords: Melanoma; Checkpoint inhibitor; Ipilimumab; Nivolumab; Switching;
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Keywords: Nivolumab; Head and Neck Neoplasms; Carcinoma, squamous cell of head and neck; Immunotherapy; Papillomaviridae (HPV, Human Papillomavirus Viruses); Programmed Cell Death 1 Receptor; CD274 protein, human (PD-L1 Protein, Human); Clinical Trial, Phase III; S
Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals
Keywords: Non-small cell lung cancer; Nivolumab; Immunotherapy; Metastatic lung cancer;
The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies
Keywords: Clinical trial design; FRACTION; Combination immuno-oncology therapy; Platform trial; Nivolumab; Ipilimumab;
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma
Keywords: Mesothelioma; Immunotherapy; Programmed death ligand 1; Nivolumab; Checkpoint inhibitor;
How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCT
Keywords: Brentuximab vedotin; Checkpoint inhibitors; Haploidentical; Nivolumab; Pembrolizumab;
Goodpasture's disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case report
Keywords: Goodpasture's disease; Immune-related adverse events; Nivolumab; Programmed cell death protein 1;
Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057
Keywords: Carcinoma; Non-small cell lung; Lung neoplasms; Docetaxel; Surveys and questionnaires; Quality of life; Nivolumab; Antineoplastic agents;
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy
Keywords: AE; adverse event; ALK; anaplastic lymphoma kinase; ALT; alanine aminotransferase; AST; aspartate aminotransferase; CI; confidence interval; CR; complete response; ECOG; Eastern Cooperative Oncology Group; EGFR; epidermal growth factor receptor; HR; hazar
Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
Keywords: Non-small cell lung cancer; Nivolumab; Peripheral blood biomarker; Prognostic factor; Predictive factor;
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
Keywords: Nivolumab; Programmed death 1 axis inhibitor; Erlotinib; Combination therapy; EGFR-mutant NSCLC;
Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study
Keywords: Advanced non-small cell lung cancer; Docetaxel; Health-related quality of life; Nivolumab; Symptom burden;
Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review
Keywords: Head and neck squamous cell carcinoma; Systematic literature review; Platinum-based chemotherapy; Pembrolizumab; Nivolumab;
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate rece
Keywords: Alefacept; Fingolimod; Infection; Ipilimumab; Natalizumab; Nivolumab; Pembrolizumab; Progressive multifocal leukoencephalopathy; Proteasome inhibitors; Vedolizumab;
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer
Keywords: Lung cancer; HIV; Pembrolizumab; Nivolumab; PD-1; PD-L1; Immunotherapy;
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)
Keywords: Non-small cell lung cancer; PD-1 inhibitor; Nivolumab; Crizotinib; anaplastic lymphoma kinase translocation;
Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients
Keywords: Nonsquamous non-small cell lung cancer; Expanded access program; nivolumab; EGFR positive; Never-smokers;
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy
Keywords: NSCLC; First line; Immunotherapy; Pembrolizumab; Nivolumab; Avelumab; Atezolizumab; Durvalumab;
Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer
Keywords: Anti-programmed cell death 1 monoclonal antibody therapy; Biomarker; Nivolumab; NSCLC; sPD-L1;
Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis
Keywords: EGFR mutation; Immunotherapy; Nivolumab; NSCLC; Radiation;
Patient-reported outcomes with nivolumab in advanced solid cancers
Keywords: Melanoma; Nivolumab; Non-small cell lung cancer; Patient-reported outcomes; Renal cell carcinoma; Head and neck cancer;
DNA mismatch repair in cancer
Keywords: 5-FU; 5-fluorouracil; bMMRD; Biallelic mismatch repair deficiency; CD28; cluster of differentiation 28; CIN; Chromosomal instable; CR; complete response; CRC; colorectal cancer; CTL; cytotoxic T-lymphocytes; CTLA-4; cytotoxic T lymphocyte antigen-4; DFS;
Rapid Response to Nivolumab in a Patient With Sarcomatoid Transformation of Chromophobe Renal Cell Carcinoma
Keywords: Chromophobe renal cell carcinoma; Nivolumab; Non-clear-cell renal cell carcinoma; Programmed death 1 inhibitor; Sarcomatoid transformation;
Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer
Keywords: NSCLC; Adenocarcinoma; EGFR; Small cell lung cancer; Transformation; Nivolumab;
Case ReportA first reported case of metastatic anorectal amelanotic melanoma with a marked response to anti-PD-1 antibody nivolumab: A case report
Keywords: Anorectal melanoma; Amelanotic melanoma; Nivolumab; Anti-PD-1 antibody;
Nivolumab and ipilimumab in the treatment of metastatic renal cell carcinoma. Report of two patients
Keywords: Immunotherapy; Metastatic renal cell carcinoma; Nivolumab; Ipilimumab;
A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
Keywords: Nivolumab; Pembrolizumab; PD-1; T-cell checkpoint;
Current PerspectiveThe 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients
Keywords: Melanoma; Adjuvant therapy; Randomised trials; Nivolumab; Ipilimumab; Dabrafenib; Trametinib;
Case reportImmunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment
Keywords: Adenocarcinoma; Lung cancer; Immunotherapy; Nivolumab; Pembrolizumab; Programmed death-ligand;
Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice
Keywords: Advanced renal cell carcinoma; Immune checkpoint inhibitor; Immunotherapy agents; Nivolumab; Second-line therapy; PD-1 inhibitor;
PD-1 checkpoint inhibition: Toxicities and management
Keywords: Immune-related adverse events; PD-1 inhibitor; PD-L1 inhibitor; Treatment; Management; Nivolumab; Pembrolizumab; Atezolizumab; Avelumab; Durvalumab;
New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group
Keywords: Non squamous NSCLC; Second line therapy; Nintedanib; Ramucirumab; Nivolumab; Pembrolizumab; Atezolizumab; Docetaxel; Therapeutic strategy;
Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients
Keywords: ALP; Alkaline Phosphatase; ALT; alanine transaminase; AST; aspartate aminotransferase; BSA; Bovine Serum Albumin; CRP; C-Reactive Protein; CV; Coefficient of Variation; ECOG; Eastern Cooperative Oncology Group; EMA; European Medicines Agency; FDA; Food an
Radiosynthesis and preclinical PET evaluation of 89Zr-nivolumab (BMS-936558) in healthy non-human primates
Keywords: Nivolumab; Opdivo; PET; Zirconium-89; PD-1; PD-L1; BMS-936558;